In Vitro Efficacy Testing Services for Phenylketonuria

We provide robust and sensitive in vitro screening and characterization platforms for accelerating the discovery and screening of potential therapies for Phenylketonuria. Our service offers customizable assays to evaluate the efficacy of compounds targeting key enzymes and pathways implicated in the disorder, such as phenylalanine hydroxylase and associated metabolic processes. By focusing on the biochemical and cellular mechanisms underlying impaired phenylalanine metabolism, we can assess both direct and indirect therapeutic interventions. Our platforms enable detailed analysis of relevant pathological processes, including phenylalanine accumulation and its cellular effects.

We offer a comprehensive suite of in vitro testing methods tailored to characterize compound activity, protein interactions, and metabolic effects in the context of Phenylketonuria. These assays are designed to evaluate drug efficacy, binding affinity, and functional outcomes using advanced biochemical and biophysical techniques. Our integrated approach ensures reliable data to support preclinical drug development.

Fluorescent assay: Utilizes fluorescence-based detection to monitor enzyme activity, substrate conversion, or cellular responses, enabling rapid and sensitive quantification of compound effects.

Isothermal titration calorimetric assay: Measures heat changes during molecular interactions, providing direct insights into binding affinities and thermodynamics between drugs and target proteins.

Leucine uptake assay: Assesses amino acid transport by quantifying cellular uptake of labeled leucine, which can serve as a surrogate for altered phenylalanine transport and metabolism.

Mass spectrometry: Offers precise quantification of metabolites, protein modifications, or compound concentrations, supporting detailed pharmacodynamic and pharmacokinetic evaluations.

Radioactivity assay: Employs radiolabeled substrates or tracers to sensitively measure enzymatic activity or metabolic flux, particularly useful for low-abundance targets.

Surface plasmon resonance assay: Enables real-time, label-free analysis of biomolecular interactions, allowing accurate determination of binding kinetics and affinities.

We measure critical pharmacological parameters such as EC-50, IC-50, and Kd to quantify compound potency, efficacy, and target binding. These metrics provide essential benchmarks for lead optimization and comparative analysis of candidate therapies. Accurate parameter determination is vital for informed decision-making in preclinical drug development.

EC-50 (Half Maximal Effective Concentration): Indicates the concentration of a compound required to achieve 50% of its maximal effect, providing a measure of compound potency and efficacy.

IC-50 (Half Maximal Inhibitory Concentration): Represents the concentration needed to inhibit a specific biological or biochemical function by 50%, essential for evaluating inhibitors targeting key enzymes or pathways.

Kd (Dissociation Constant): Reflects the affinity between a drug and its target protein, with lower values indicating stronger binding; critical for assessing binding strength and optimizing lead compounds.

Recommended In Vitro Efficacy Tests

Phenylalanine Hydroxylase

Our Phenylalanine Hydroxylase (PAH) testing service supports Phenylketonuria (PKU) drug development by evaluating PAH activity, a key enzyme deficient in PKU. Accurate assessment is crucial for identifying effective therapies. Using mass spectrometry, surface plasmon resonance, and isothermal titration calorimetry, we quantify drug-PAH interactions, determining main parameters such as EC-50 and Kd to guide drug optimization and efficacy evaluation.

Solute Carrier Family 6 Member 19

Solute Carrier Family 6 Member 19 (SLC6A19) mediates neutral amino acid transport, affecting phenylalanine levels in Phenylketonuria (PKU). Testing SLC6A19 function is crucial for PKU drug development to assess compound efficacy in modulating transporter activity. Key methods include radioactivity and leucine uptake assays, evaluating inhibitor potency by determining IC-50 values, which reflect the concentration needed to reduce SLC6A19 activity by 50%.

Transmembrane Serine Protease 15

Transmembrane Serine Protease 15 (TMPRSS15) is implicated in protein digestion and may influence phenylalanine metabolism in Phenylketonuria (PKU). Testing TMPRSS15 activity is vital for PKU drug development to assess potential therapeutic effects. Our service utilizes a sensitive fluorescent assay to measure TMPRSS15 inhibition, providing quantitative IC-50 values to evaluate compound potency and efficacy in modulating enzyme activity relevant to PKU treatment strategies.